Merck close to $6B acquisition of Terns Pharma to boost cancer portfolio: FT (MRK:NYSE)

Merck is reportedly nearing a $6 billion all-cash deal to acquire Terns Pharmaceuticals. This strategic move aims to strengthen Merck’s drug pipeline, especially in anticipation of its blockbuster cancer treatment Keytruda’s patent expiration. The acquisition would enhance Merck’s oncology portfolio.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin